PROJECT DETAILS
Market
United Kingdom
HTA Body
NICE
Evidence Type
PRO/QOL Data Package
Capabilities
HTA Strategy, Evidence Synthesis, Regulatory Alignment
HTA Strategy
PRO/QOL
Market Access
Strategic PRO/QOL Evidence for Successful UK HTA Submission
Developing a comprehensive patient-reported outcomes and quality of life evidence strategy to support a successful NICE submission for a specialty therapeutic.
📊
HTA Evidence Strategy
✓
Successful Outcome
QOL
Data Strategy
PRO
Evidence Package
NICE
HTA Submission
the challenge
Building the PRO/QOL Case for NICE
A pharmaceutical company was preparing a NICE submission for a specialty therapeutic in a disease area where patient-reported outcomes and quality of life data would be critical to demonstrating value beyond traditional clinical endpoints.
The challenge was twofold: the existing clinical program had PRO data, but it hadn't been collected or analyzed with UK HTA requirements specifically in mind. Additionally, the company needed to demonstrate improvements in quality of life that would translate into QALY gains for the economic model.
"NICE's focus on patient experience and quality of life meant our PRO strategy would be central to the submission's success—not supplementary to it."
Our Approach
Comprehensive Evidence Development
We developed a strategic approach to maximize the PRO/QOL evidence package for the NICE submission.
01
Gap Analysis
Assessed existing PRO data against NICE requirements to identify evidence gaps and opportunities for strengthening the submission.
02
Instrument Validation
Ensured PRO instruments met psychometric standards required by NICE and could support utility mapping for economic modeling.
03
Utility Mapping
Developed methodology to map disease-specific PRO data to EQ-5D utilities for QALY calculations.
04
Narrative Development
Created compelling patient experience narrative supported by quantitative PRO evidence for the submission document.
"
The PRO/QOL evidence package provided the foundation for demonstrating meaningful patient benefit that translated directly into the economic case for reimbursement.
Project Outcome
the results
Successful NICE Outcome
The comprehensive PRO/QOL strategy contributed to a successful NICE submission outcome.
📋
Complete
Evidence package meeting NICE standards
✓
Success
NICE submission achieved positive outcome
📈
Mapped
PRO data to EQ-5D utilities for QALY gains
key insights
UK HTA Best Practices
1
PRO Strategy Starts Early
Aligning PRO collection with HTA requirements during clinical development prevents evidence gaps at submission.
2
Utility Mapping Is Critical
NICE requires EQ-5D utilities—mapping strategies from disease-specific instruments must be robust and validated.
3
Patient Narrative Matters
Quantitative PRO data is strengthened by qualitative patient experience evidence that brings the numbers to life.
4
Psychometric Rigor Required
NICE scrutinizes instrument validity—ensuring robust psychometric properties is essential for acceptance.
Planning an HTA Submission?
Let's discuss how to build the PRO/QOL evidence package that HTA bodies require for positive outcomes.